齐鲁制药创新药物全球研发总部落地上海，总投资约30亿元

Core Viewpoint - Qilu Pharmaceutical Group is establishing a global R&D headquarters in Zhangjiang Science City, Shanghai, with a total investment of approximately 3 billion yuan, focusing on innovative drug development in areas such as oncology and autoimmune diseases [2][4]. Group 1: Company Overview - Qilu Pharmaceutical is a large modern pharmaceutical enterprise in China, engaged in the research, production, and sales of drugs for various diseases, including oncology and cardiovascular conditions [2][3]. - The company has over 300 products on the market, with a sales network that extends to North America, Europe, Japan, and Australia, establishing partnerships with global firms like Pfizer and Novartis [3][5]. - Qilu has been recognized as the 3rd largest pharmaceutical company in China by the Ministry of Industry and Information Technology in 2023, reflecting its leading position in the domestic pharmaceutical industry [4]. Group 2: R&D Investment and Achievements - The company has committed to a stable annual R&D investment of 4.38 billion yuan in 2024, which constitutes 12% of its sales revenue, with a projected total R&D investment exceeding 20 billion yuan during the 14th Five-Year Plan period [4][5]. - Qilu has developed numerous significant new drugs, including Erlotinib and Bevacizumab, and has received over 100 invention patents, contributing to its strong innovation capabilities [4][5]. - The company has established a comprehensive technology innovation management system, focusing on both innovative and generic drugs, creating a "dual-drive" development model [4]. Group 3: Global Market Expansion - Qilu's products are sold in over 100 countries and regions, with 31 formulations exported to the U.S. and 17 to Europe, demonstrating its competitive position in the global pharmaceutical market [6][8]. - The company has achieved significant market shares in various regions, with 38 products holding the top market position in their respective countries [6][8]. - Qilu has set up four innovation centers in the U.S. to enhance its global R&D layout, forming a complete innovation development system that covers the entire process from early discovery to commercialization [5][8]. Group 4: Strategic Development in Zhangjiang - The new global R&D headquarters in Zhangjiang Science City will cover a total area of approximately 46,000 square meters, with a focus on creating a collaborative innovation environment [7][8]. - This strategic move follows the establishment of the Shanghai R&D center in 2018 and aims to leverage Shanghai's strong biopharmaceutical ecosystem to drive high-quality industry development [8][9]. - The collaboration is expected to enhance resource integration and collaborative innovation, contributing to the development of a new highland for the biopharmaceutical industry in Shanghai [8][9].